跳至主要内容
临床试验/EUCTR2018-000770-29-IE
EUCTR2018-000770-29-IE进行中(未招募)1 期

Investigating the role of early low-dose aspirin in diabetes: A phase III multicentre double-blinded placebo-controlled randomised trial of low-dose aspirin initiated in the first trimester of diabetes pregnancy - IRELAnD

The Rotunda Hospital0 个研究点目标入组 360 人开始时间: 2018年6月11日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
360

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • Ability to comprehend the Patient Information Leaflet and to provide signed and dated informed consent.
  • Willing to comply with all study procedures and be available for the duration of the study
  • Female, age >18 years
  • Singleton pregnancy, ongoing at 11 – 13+6 weeks’ gestation
  • Pre-pregnancy diagnosis of type I or type II diabetes of at least 6 months’ duration
  • Fulfillment of each criterion must be clearly evidenced (in lab reports or correspondence) and/or documented in the medical records.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 360
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Aspirin hypersensitivity (prior bronchospasm/ urticarial/ angioedema with aspirin)
  • Active or recurrent peptic ulceration (2 or more distinct episodes of proven ulceration or bleeding), repetitive gastric symptoms or history of intolerance of NSAIDs
  • Known bleeding diathesis (hypothrombinaemia, haemophilia, von Willebrands’ disease)
  • Multifetal gestation
  • Breastfeeding
  • Severe early-onset preeclampsia in a previous pregnancy
  • Patient already on aspirin at the time of screening
  • Established chronic renal disease (progressive loss of renal function of at least 3 months’ duration), clinically significant liver disorder, hyperuricemia (Gout), glucose-6-phosphate dehydrogenase (G6PD) deficiency or heart failure (This exclusion criterion will be assessed from patient’s medical history not from screening laboratory tests).
  • Blood clotting disorder or treatment with anticoagulants at the time of recruitment or with anti-platelet therapy (Anticoagulants commenced after recruitment will not constitute exclusion from the trial).
  • Macroalbuminuria (24-hour urinary protein 300g or greater, or spot urinary protein/creatinine ratio >0.3 in the first trimester or dipstick proteinuria >/= +2
  • Chronic hypertension (antihypertensive therapy in first trimester)
  • Inability to speak or read English
  • Use of any other medication that would constitute a risk to a patient taking aspirin in the opinion of the investigator ((including Interferon-a and Methotrexate)
  • Inflammatory bowel disease (Crohn’s disease or Ulcerative colitis)
  • Use of any other investigational medicinal product within the previous 30 days
  • The presence of any illness or condition that might interfere with the patient’s ability to comply with the study procedures
  • The presence of any illness or condition (including recent surgery) that renders the patient unsuitable for treatment with aspirin in the opinion of the investigator
  • Hyperemesis gravidarum

研究者

发起方
The Rotunda Hospital

相似试验